Third-line therapy for chronic myeloid leukemia: current status and future directions
Jörge E. Cortes(The University of Texas MD Anderson Cancer Center), Fabian Lang(Goethe University Frankfurt)
Cited by 115
Related Papers
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
|Haematologica|2010|204